|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
December 20, 2005Bayhill Therapeutics reports positive MS trial
Bayhill is conducting a phase I/II trial with its drug BHT-3009 involving 30 patients at four medical centers in North America. The drug has demonstrated an effect on certain T cells, which, when they become pathogenic, cause the autoimmune disease MS.
"The Bayhill research is one of the first hints that scientists engaged in multiple sclerosis drug discovery can directly and specifically affect MBP-specific T-cells in humans," Bayhill said in a press release.MORE |